|
KMID : 1039420210550030181
|
|
Journal of Pathology and Translational Medicine
2021 Volume.55 No. 3 p.181 ~ p.191
|
|
|
Molecular biomarker testing for non?small cell lung cancer: consensus statement of the Korean Cardiopulmonary Pathology Study Group
|
|
Chang Sun-Hee
Shim Hyo-Sup
Kim Tae-Jung
Choi Yoon-La
Kim Wan-Seop
Shin Dong-Hoon
Kim Lucia
Park Heae-Surng
Lee Geon-Kook
Lee Chang-Hun
|
|
|
Abstract
|
|
|
|
Molecular biomarker testing is the standard of care for non?small cell lung cancer (NSCLC) patients. In 2017, the Korean Cardiopulmonary Pathology Study Group and the Korean Molecular Pathology Study Group co-published a molecular testing guideline which contained almost all known genetic changes that aid in treatment decisions or predict prognosis in patients with NSCLC. Since then there have been significant changes in targeted therapies as well as molecular testing including newly approved targeted drugs and liquid biopsy. In order to reflect these changes, the Korean Cardiopulmonary Pathology Study Group developed a consensus statement on molecular biomarker testing. This consensus statement was crafted to provide guidance on what genes should be tested, as well as methodology, samples, patient selection, reporting and quality control.
|
|
|
KEYWORD
|
|
|
Carcinoma, non-small-cell lung, Biomarker, Precision medicine, Consensus
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|